Department of Dermatology, Huizhou Municipal Central Hospital, Huizhou 516000, Guangdong, People's Republic of China.
Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, People's Republic of China.
Int J Med Sci. 2022 Jan 1;19(1):195-204. doi: 10.7150/ijms.66929. eCollection 2022.
Human fibroleukin 2 (Fgl2), a member of the fibrinogen superfamily, can cleave prothrombin to generate thrombin or is secreted in a soluble form as a new type of effector of Tregs with immunomodulatory functions. However, there is little research on the role of Fgl2 in cutaneous squamous cell carcinoma (CSCC) growth. We examined the expression of Fgl2 in samples from CSCC patients and CSCC cell lines. Then, the effect of Fgl2 on CSCC was evaluated and in animals. Regulation of autophagy by Fgl2 was explored in CSCC. Coimmunoprecipitation (Co-IP) and immunofluorescence colocalization experiments were conducted to identify the regulatory effect of Fgl2 on the downstream protein Tyrobp. Then, gain- or loss-of-function analyses and evaluation of Tyrobp expression were performed to validate its role in autophagy and proliferation promoted by Fgl2. Here, our study demonstrated that Fgl2 promoted the proliferation of CSCC cells and . Knocking down Fgl2 reduced CSCC cell proliferation and inhibited autophagy in CSCC. Mechanistically, Fgl2 interacted with Tyrobp and promoted ERK-dependent autophagy, resulting in the proliferation of CSCC cells. Our study suggested that Fgl2 could be a promising prognostic biomarker and useful therapeutic target for CSCC.
人纤维介素 2(Fgl2)是纤维蛋白原超家族的一员,可将凝血酶原裂解生成凝血酶,或作为具有免疫调节功能的 Tregs 的新型效应物以可溶性形式分泌。然而,关于 Fgl2 在皮肤鳞状细胞癌(CSCC)生长中的作用的研究甚少。我们检查了 Fgl2 在 CSCC 患者和 CSCC 细胞系样本中的表达。然后,评估了 Fgl2 对 CSCC 的影响以及在动物中的影响。探讨了 Fgl2 对 CSCC 自噬的调节作用。通过共免疫沉淀(Co-IP)和免疫荧光共定位实验,鉴定了 Fgl2 对下游蛋白 Tyrobp 的调节作用。然后,进行了 gain-或 loss-of-function 分析和 Tyrobp 表达的评估,以验证其在 Fgl2 促进的自噬和增殖中的作用。在这里,我们的研究表明 Fgl2 促进了 CSCC 细胞的增殖。敲低 Fgl2 可降低 CSCC 细胞的增殖并抑制 CSCC 中的自噬。在机制上,Fgl2 与 Tyrobp 相互作用并促进 ERK 依赖性自噬,从而导致 CSCC 细胞的增殖。我们的研究表明,Fgl2 可能是 CSCC 的有前途的预后生物标志物和有用的治疗靶标。